Trials / Completed
CompletedNCT00410761
An Efficacy Study Comparing ZD6474 to Placebo in Medullary Thyroid Cancer
An International, Phase III, Randomized, Double-Blinded, Placebo-Controlled, Multi-Center Study to Assess the Efficacy of ZD6474 (ZACTIMATM) Versus Placebo in Subjects With Unresectable Locally Advanced or Metastatic Medullary Thyroid Cancer
- Status
- Completed
- Phase
- Phase 3
- Study type
- Interventional
- Enrollment
- 331 (actual)
- Sponsor
- Genzyme, a Sanofi Company · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of this study is to learn how hereditary or sporadic medullary thyroid cancer patients, treated with ZD6474, react to the drug, what happens to ZD6474 in the human body, about the side effects of ZD6474, and if ZD6474 can decrease or prevent the growth of tumors.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | ZD6474 (Vandetanib) | once daily oral tablet |
Timeline
- Start date
- 2006-11-23
- Primary completion
- 2009-07-31
- Completion
- 2024-07-26
- First posted
- 2006-12-13
- Last updated
- 2025-09-24
- Results posted
- 2012-03-26
Locations
127 sites across 24 countries: United States, Australia, Austria, Belgium, Brazil, Canada, Czechia, Denmark, France, Germany, Hungary, India, Italy, Mexico, Netherlands, Poland, Portugal, Romania, Russia, Serbia, South Korea, Spain, Sweden, Switzerland
Source: ClinicalTrials.gov record NCT00410761. Inclusion in this directory is not an endorsement.